Zafgen Inc. Security Rating

Larimar Therapeutics (formerly known as Zafgen) is a biopharmaceutical company dedicated to improving the health and well-being of patients affected by obesity and complex metabolic disorders. The company is focused on developing novel therapeutics that treat the underlying biological mechanisms through the methionine aminopeptidase 2, or MetAP2, pathway. Larimar Therapeutics has pioneered the study of MetAP2 inhibitors in both common and rare forms of obesity. The Company's lead product candidate is ZGN-1061, a novel fumagillin-class MetAP2 inhibitor administered by subcutaneous injection, which is currently being profiled for its utility in the treatment of metabolic diseases including type 2 diabetes and obesity.Larimar Therapeutics is conducting a Phase 1 clinical trial of ZGN-1061 in the Netherlands, and have completed dosing patients in the single ascending dose, or SAD, portion and are currently dosing patients in the multiple ascending dose, or MAD, portion. This clinical trial is evaluating ZGN-1061 for safety, tolerability, and pharmacokinetics while also gaining an early indication of weight loss efficacy over four weeks of treatment.